Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando Muñoz

Showing results (271-280 of 281) with videos related to

Pageof 29
Sort By:
Postgraduate Medical Journal|June 24, 2024
Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA projectCarlos González-Muñoza, Margalida Calafat, Javier P Gisbert, et al.
Journal of Crohn'S & Colitis|February 1, 2022
Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCUManuel Barreiro-de Acosta, Sabino Riestra, Margalida Calafat, et al.
Frontiers in Medicine|February 18, 2022
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native PatientsAna Gutiérrez, Pedro Zapater, Elena Ricart, et al.
The American Journal of Gastroenterology|December 14, 2022
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCUManuel Barreiro-de Acosta, Agnès Fernández-Clotet, Francisco Mesonero, et al.
Journal of Crohn'S & Colitis|August 1, 2022
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA RegistryDiego Casas-Deza, Luis Javier Lamuela-Calvo, Fernando Gomollón, et al.
The American Journal of Gastroenterology|January 30, 2023
Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and SafetyMaría Chaparro, Diana Acosta, Cristina Rodríguez, et al.
Alimentary Pharmacology & Therapeutics|August 8, 2025
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDACristina Rubín de Célix, Elena Ricart, M Dolores Martín-Arranz, et al.
Journal of Clinical Medicine|January 21, 2022
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA RegistryYamile Zabana, Ignacio Marín-Jiménez, Iago Rodríguez-Lago, et al.
Journal of Clinical Medicine|December 23, 2022
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case-Control Study (COVID-19-EII)Yamile Zabana, Ignacio Marín-Jiménez, Iago Rodríguez-Lago, et al.
Alimentary Pharmacology & Therapeutics|September 17, 2024
Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES studyMaría Chaparro, Sandra Hermida, Diana Acosta, et al.
Pageof 29

Showing results (271-280 of 281) with videos related to

Sort By:
Pageof 29
Postgraduate Medical Journal|June 24, 2024
Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA projectCarlos González-Muñoza, Margalida Calafat, Javier P Gisbert, et al.
Journal of Crohn'S & Colitis|February 1, 2022
Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCUManuel Barreiro-de Acosta, Sabino Riestra, Margalida Calafat, et al.
Frontiers in Medicine|February 18, 2022
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native PatientsAna Gutiérrez, Pedro Zapater, Elena Ricart, et al.
The American Journal of Gastroenterology|December 14, 2022
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCUManuel Barreiro-de Acosta, Agnès Fernández-Clotet, Francisco Mesonero, et al.
Journal of Crohn'S & Colitis|August 1, 2022
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA RegistryDiego Casas-Deza, Luis Javier Lamuela-Calvo, Fernando Gomollón, et al.
The American Journal of Gastroenterology|January 30, 2023
Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and SafetyMaría Chaparro, Diana Acosta, Cristina Rodríguez, et al.
Alimentary Pharmacology & Therapeutics|August 8, 2025
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDACristina Rubín de Célix, Elena Ricart, M Dolores Martín-Arranz, et al.
Journal of Clinical Medicine|January 21, 2022
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA RegistryYamile Zabana, Ignacio Marín-Jiménez, Iago Rodríguez-Lago, et al.
Journal of Clinical Medicine|December 23, 2022
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case-Control Study (COVID-19-EII)Yamile Zabana, Ignacio Marín-Jiménez, Iago Rodríguez-Lago, et al.
Alimentary Pharmacology & Therapeutics|September 17, 2024
Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES studyMaría Chaparro, Sandra Hermida, Diana Acosta, et al.
Pageof 29